Literature DB >> 2032812

The role of wax and sterol ester fatty acids in chronic blepharitis.

J M Dougherty1, J K Osgood, J P McCulley.   

Abstract

The authors analyzed the long-chain fatty acids derived from the wax and sterol ester fractions of meibomian secretions from patients with chronic blepharitis and normal individuals. Meibomian secretions were partitioned into separate lipid classes by thin-layer chromatography (TLC). Wax and sterol esters were eluted and transesterified. The liberated fatty acid methyl esters (FAME) were analyzed by gas liquid chromatography. Equivalent chain lengths (ECL) were determined for the 58 peaks found. Thirty-three peaks were positively identified by standards. Peaks were quantified by area normalization. Percentage compositions were computed for each individual and tabulated by group; each fatty acid was analyzed by analysis of variance, and each clinical group was compared with normal subjects. The authors found increases in the series of monounsaturated fatty acids from patient wax/sterol esters compared with normal subjects (P less than 0.05). The authors also found differences in some members of the series of normal, straight, and branched saturated moieties. These differences between normal groups and the blepharitic groups represent a biologically significant pattern that may relate to the disease process. Discriminant analysis provided a 73% probability of correct classification into clinical groups based strictly on FAME analysis (P less than 0.05).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2032812

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  18 in total

1.  Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study.

Authors:  Gary N Foulks; Douglas Borchman; Marta Yappert; Shelley Kakar
Journal:  Cornea       Date:  2013-01       Impact factor: 2.651

Review 2.  Interventions for chronic blepharitis.

Authors:  Kristina Lindsley; Sueko Matsumura; Elham Hatef; Esen K Akpek
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

3.  Evaluation and quantitation of intact wax esters of human meibum by gas-liquid chromatography-ion trap mass spectrometry.

Authors:  Igor A Butovich; Juan C Arciniega; Hua Lu; Mike Molai
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-06-20       Impact factor: 4.799

Review 4.  The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland.

Authors:  Erich Knop; Nadja Knop; Thomas Millar; Hiroto Obata; David A Sullivan
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-30       Impact factor: 4.799

Review 5.  [Blepharitis component of dry eye syndrome].

Authors:  C Auw-Hädrich; T Reinhard
Journal:  Ophthalmologe       Date:  2018-02       Impact factor: 1.059

6.  Topical azithromycin therapy for meibomian gland dysfunction: clinical response and lipid alterations.

Authors:  Gary N Foulks; Douglas Borchman; Marta Yappert; Sung-Hye Kim; John W McKay
Journal:  Cornea       Date:  2010-07       Impact factor: 2.651

Review 7.  Lipidomics of human Meibomian gland secretions: Chemistry, biophysics, and physiological role of Meibomian lipids.

Authors:  Igor A Butovich
Journal:  Prog Lipid Res       Date:  2011-03-31       Impact factor: 16.195

8.  A compositional based model for the tear film lipid layer.

Authors:  J P McCulley; W Shine
Journal:  Trans Am Ophthalmol Soc       Date:  1997

Review 9.  [Chronic blepharitis. Pathogenesis, clinical features, and therapy].

Authors:  C Auw-Haedrich; T Reinhard
Journal:  Ophthalmologe       Date:  2007-09       Impact factor: 1.059

10.  Lipidomic analysis of human tear fluid reveals structure-specific lipid alterations in dry eye syndrome.

Authors:  Sin Man Lam; Louis Tong; Bastien Reux; Xinrui Duan; Andrea Petznick; Siew Sian Yong; Cynthia Boo Shiao Khee; Martin J Lear; Markus R Wenk; Guanghou Shui
Journal:  J Lipid Res       Date:  2013-11-28       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.